A multicenter randomized phase III trial to compare weekly usage with triple weekly usage of paclitaxel concurrent with radiotherapy for patients with locally advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000786

Enrollment

Unknown

Registered

2010-02-07

Start date

2007-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced non-small cell lung cancer

Interventions

1:The concurrent chemotherapy consisted of paclitaxel 15mg/m2, three times a week, 6 weeks in total.

2:The concurrent chemotherapy consisted of paclitaxel 45mg/m2, once weekly, 6 weeks in total.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed unresectable stage IIIA or stage IIIB non-small cell lung; 2. At least 1 bidimensionally or unidimensionally measurable lesion less than 8cm; 3. Age: 18-75 years old, no more than 10% weight loss within past 6 months, life expectancy >12 months and tolerent radiation; 4. The ECOG 0-1; 5. No main organ function disable, Leucocyte>= 4000/uL, a neutrophil count>=1500/uL, PLT >=10000/uL, hemoglobin>=10g/dL, CR=1.5 L and >50% upper limit of normal; 6. No chest RT history and no other treatment for cancer in the last month.Patients who received induction chemotherapy 8cm); 7. Patients shoud understand and sign the Informed consent.

Exclusion criteria

Exclusion criteria: 1. Carcinoid tumors and small cell lung cancer; 2. Patients who received induction chemotherapy >4 cycle. Patients are receiving other anti-cancer therapy, and pregnant and lactating women; 3. Patients with a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma; 4. Active infection, uncontrolled diabetes, prior allergic reaction to paclitaxel; 5. Inadequent liver and renal function; 6. Other serious disease, for example myocardial infarction; 7. Uncontrolable madman psychopath; 8. Investigator consider inappropriate patients for the study.

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS);PFS, 2 and 5 year OS, MS;Median survival (MS);The 2 and 5-year overall survival (OS);	—

Secondary

Measure	Time frame
Response rate and toxicity;	—

Countries

China

Contacts

Public ContactGuangying Zhu

zgypu@yahoo.com.cn+86 010 88196120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 8, 2026